Clinical trial · Interventional
Toripalimab Combined With Beat Chemotherapy in the Treatment of Advanced Back-line Small Cell Lung Cancer
A Prospective, Open-label, Bayesian Adaptive Randomized Phase II Clinical Study of Toripalimab Combined With Beat Chemotherapy in the Treatment of Advanced Back-line Small Cell Lung Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is a randomized, open-label, multi-center investigator-initiated clinical trial. Patients who meet the inclusion criteria receive the treatment plan stipulated in the protocol. A Bayesian design is used to explore the efficacy and safety of teprotumumab combined with pulse chemotherapy in the treatment of advanced second-line extensive-stage small cell lung cancer.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bayesian | — | UNRESOLVED | — |
| Metronomic Chemotherapy | — | UNRESOLVED | — |
| SCLC, Extensive Stage | Lung Small Cell Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Toripalimab; Etoposide | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (5)
- type
- EXPERIMENTAL
- label
- Etoposide
- description
- Etoposide: PO, 50 mg, d1-d14, Q3W
- interventionNames
- Drug: Toripalimab; Etoposide
- type
- EXPERIMENTAL
- label
- Etoposide+Toripalimab
- description
- Toripalimab: 240 mg ,D1, ivgtt, Q3W; Etoposide: PO, 50 mg, d1-d14 ，Q3W；
- interventionNames
- Drug: Toripalimab; Etoposide
- type
- EXPERIMENTAL
- label
- Toripalimab+Etoposide+Anlotinib
- description
- Toripalimab: 240 mg ,D1, ivgtt, Q3W; Etoposide: PO, 50 mg, d1-d14 ，Q3W； Anlotinib: 12mg, d1-d14, PO, Q3W;
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * 1.Age ≥18 years old, both male and female are acceptable. * 2\. Histology and pathology diagnosis of extensive stage small cell lung cancer, and must meet the following standards: 1. always has not received the immune therapy, 2. Previously received immunotherapy, with the number of treatment lines ≥2 and the immunotherapy being effective(immunotherapy PFS \> 3 months, withdrawal time \> 3 months) 3. never used anlotinib, * 3\. ECOG: 0 \~ 2; * 4 . The expected lifetime 12 weeks or more; * 5\. Major organs function normal Exclusion Criteria: * 1.Those who are allergic to toripalimab or etoposide or have metabolic disorders; * 2.With known the special ripley sheet resistance, etoposide contraindication; * 3.Other circumstances that the researcher assessed as unsuitable for participation in this clinical study.
References
Publications (0)
Data not yet available